Since the deletion or inhibition of SOCS1 and SOCS3 in T cells or myeloid cells enhances anti-tumor immunity, SOCS inhibitors may be ideal drugs for targeting immune checkpoints controlled by cytokines (193). The gene discussed is CISH; the disease is neoplasm.